Novo Nordisk (NVO) continues to draw investor attention after recent share price moves, with the stock last closing at $43.19. The company’s performance metrics now invite closer scrutiny of its valuation and growth profile.

Recent trading has been slightly softer, with a 1-day share price return of 0.76% and a 7-day share price return of 1.75%. The 90-day share price return of 18.23% contrasts with a year to date share price decline of 17.56% and a 1-year total shareholder return decline of 39.72%. This suggests that near term momentum has picked up after a weaker period for longer term holders.

If Novo Nordisk has sharpened your focus on long term themes in healthcare, it can be useful to see what else is moving in specialist areas such as 41 healthcare AI stocks

With Novo Nordisk shares weaker over the year but showing a strong 90 day rebound and trading below some valuation estimates, the key question is whether you are seeing an undervalued leader or a stock that is already priced for future growth.

Most Popular Narrative: 54.5% Undervalued

Novo Nordisk’s most followed valuation narrative puts fair value at $95 per share versus the last close of $43.19. This frames the stock as heavily discounted and raises questions about what the market might be missing.

Current sentiment has swung deeply negative, but expectations are now low. If Novo delivers even moderate execution, sustaining semaglutide momentum, expanding label indications, and avoiding further policy shocks, the embedded upside is material.

The fair value hinges on how long the GLP 1 franchise can compound, how margins hold up as pricing shifts, and what success is priced in for follow on obesity drugs. The narrative leans on detailed assumptions about revenue growth, profitability and what multiple the market might eventually pay, but the exact mix of drivers is not obvious from the headline number alone.

Result: Fair Value of $95 (UNDERVALUED)

However, this depends on Novo Nordisk maintaining its GLP 1 pricing power and preventing policy pressure or new obesity competition from eroding margins faster than expected.

Next Steps

If this mix of concern and optimism around Novo Nordisk leaves you undecided, take a closer look at the data now and weigh both sides through 3 key rewards and 4 important warning signs

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your interest, do not stop here; broaden your watchlist with focused screeners that surface different types of opportunities other investors might overlook.

• Spot potential value standouts early by scanning companies that combine quality fundamentals with attractive prices through the 45 high quality undervalued stocks.
• Prioritize resilience by zeroing in on businesses with strong finances using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for future leaders before the crowd notices by sifting through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.